srdr.ahrq.govSRDR Systematic Review Data Repository™ Agency for

Your web browser does not support Javascript, or you have it turned off. Please turn on Javascript or use a Javascript-compatible web browser to take advantage of the full functionality of SRDR. Browser does not support iframes. Please update your browser to for a better viewing experience. SRDR Header Links -- Skip to SRDR Navigation User Search Parameters Try the SRDR Training Site | Login | Register | Feedback | Help & Training | About Us | Contact Us | Citing SRDR | Usage Policies Home Published Projects Registries Advanced Search Home Select a Topic: User Home Screen Extraction Forms Project Creation Study Creation Preview Pages Other Your Feedback: Submit Reset Cancel -- Welcome to the Systematic Review Data Repository The Systematic Review Data Repository (SRDR) is a powerful and easy-to-use tool for the extraction and management of data for systematic review or meta-analysis. It is also an open and searchable archive of systematic reviews and their data. New Announcement RSVP Today for SRDR Training Webinars! Need Assistance During the Holidays? -- Scheduled maintenance in day(s). Click me for more details. -- To contribute data or comment on deposited projects, simply Register for an account. Registered users, log in below: Username: Password: Remember Me -- Log In Forgot Password Forgot Password? Recently Completed and Deposited Reports Data -- Latest Most Viewed Blood Pressure Targets in CKD Public Report Complete Statistics: 3 Studies, 2 Key Questions, 1 Extraction Form, Date Created: Jul 02, 2012 08:35PM Description: Background: The optimal blood pressure target in patients with chronic kidney disease (CKD) is unclear. Purpose: To summarize trials comparing lower versus higher blood pressure targets in adult patients with CKD and focus on proteinuria as an effect modifier. SRDR Project Indexing Public Report Complete Statistics: 161 Studies, 1 Key Question, 1 Extraction Form, Date Created: May 20, 2018 11:24PM Description: This is a Methods Research project that catalogs the various projects with publicly available data on the SRDR Webpage. Three types of hypoglycemic agents (DPP- 4Is, GLP-1RAs, SGLT-2Is) for patients with type 2 diabetes: effectiveness and safety evaluation network meta-analysis Public Report Complete Statistics: 9 Studies, 1 Key Question, 1 Extraction Form, Date Created: Jan 19, 2020 09:48AM Description: Objective: In view of the development of hypoglycemic agents in recent years and the growth in the number of people with type 2 diabetes mellitus(T2DM), latest information is needed for clinicians and patients to make more reliable decisions. The objective of this systematic review database is to summarize and compare the effectiveness and possible safeties of the current three new types of hypoglycemic agents: dipeptidyl peptidase-4 inhibitors[DPP- 4Is], glucagon-like peptide-1 receptor agonists[GLP-1RAs] and sodium-dependent glucose transporters 2 inhibitors[SGLT-2Is]. Data Sources: We searched the MEDLINE, Embase and Cochrane Library databases for original English-language articles, and collected unpublished studies’ data from clinicaltrial.org and other sources. We included all randomized controlled trials (RCTs) that use any of these three types of hypoglycemic agents as interventions in comparison groups, and the searching process is now updated to March 2019. Results: This systematic review database contains three types of hypoglycemic agents: DDP-4Is, GLP-1RAs and SGLT-2Is, which involved in 441,338 and 573 RCTs respectively. We recorded the baseline characteristics of patients and outcome indicators, which include gender, age, duration of type 2 diabetes, and the level of HbA1c, FPG, PPG, LDL, HDL, TC, body weight, BMI, blood pressure, heart rate, etc. Additionally, we included almost all adverse events that were observed in studies to obtain comprehensive information, for instance: digestive system disorders(e.g. nausea, diarrhea, decreased appetite, hyperchlorhydria); cardiovascular system dysfunctions(e.g. stroke, angina pectoris, arrhythmia, myocardial infarction); liver and renal impairments(e.g. renal stone, acute renal failure, hepatic encephalopathy, hepatic steatosis); musculoskeletal disorders(e.g. arthtitis, fracture, muscular weakness); various types of infections and neural disorders, etc. The data extraction and quality evaluation process now is partly done, and we have been keeping the database updated. Next, we will select the appropriate information from this database for deeper statistical analysis, and complete systematic reviews and meta-analysis. Conclusions: Till today, the existing results of original researches on the effectiveness and safety of three type of hypoglycemic drugs are diverse, and related systematic reviews are still incomplete. For example, study had shown that SGLT-2Is improve cardiovascular function in T2DM patients with coronary artery disease or chronic kidney dysfunction compared to DPP-4Is; DPP-4Is(sitagliptin)may exert a less potent effect on HbA1C, FPG, PPG, and weight reduction than GLP-1 receptor agonists in obese or overweight patients; There are also differences between different drugs in one single type. Observing the effects of hypoglycemic drugs requires studies with large samples and long term observation. Therefore, better evidences are needed to provide a compelling reason for their use in different situations and different population subgroups. All of comprehensive information was included in this database, which is essential for further statistical analysis. Studies that focus on a single outcome have certain limitations. So in the future, we will use this database to explore the benefit-risk of these drugs with multiple outcomes. The models we are interested in are multi-criteria decision analysis (MCDA) model and its derivative model stochastic multicriteria acceptability analysis (SMAA). When we conduct benefit/risk analysis, we will make good use of indirect comparative studies through network meta-analysis. Through the comparison within or between three types of hypoglycemic agents, we may hopefully provide more reliable conclusions for clinicians and patients to develop personalized treatment plans and gain the greatest health benefit for patients. Skin Substitutes for Treating Chronic Wounds Public Report Complete Statistics: 22 Studies, 1 Key Question, 1 Extraction Form, Date Created: Mar 28, 2020 07:41PM Description: Systematic review to describe skin substitute products commercially available in the United States used to treat chronic wounds, examine systems used to classify skin substitutes, identify and assess randomized controlled trials (RCTs), and suggest best practices for future studies. Opioid Treatments for Chronic Pain Public Report Complete Statistics: 175 Studies, 4 Key Questions, 1 Extraction Form, Date Created: Mar 09, 2020 05:49PM Description: To assess the effectiveness and harms of opioid therapy for chronic noncancer pain; alternative opioid dosing strategies; and risk mitigation strategies Screening for Hepatitis C Virus Infection in Adolescents and Adults: A Systematic Review Update for the U.S. Preventive Services Task Force [Entered Retrospectively] Public Report Complete Statistics: 94 Studies, 9 Key Questions, 1 Extraction Form, Date Created: Mar 05, 2020 08:41PM Description: Background: Prior reviews on hepatitis C (HCV) infection screening and treatment used by the U.S. Preventive Services Task Force (USPSTF) to inform its 2013 recommendation found interferon-containing antiviral therapies associated with sustained virologic response (SVR) rates of 68 percent to 78 percent and an association between SVR after antiviral therapy and improved clinical outcomes. Interferon-containing regimens were associated with a high rate of harms. Since the prior reviews, interferon-containing antiviral therapies have been replaced by all-oral direct acting antiviral (DAA) regimens. Purpose: To systematically review the evidenc...